Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-07-02T16:55:47.948Z Has data issue: false hasContentIssue false

Alprazolam addiction: The case study

Published online by Cambridge University Press:  13 August 2021

O. Pityk*
Affiliation:
Psychiatry, Narcology And Medical Psychology Department, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
N. Karbovskyi
Affiliation:
Student, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
N. Galyga
Affiliation:
Neuroses And Borderline Disorders Department, Precarpathian Regional Clinical Center of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine
O. Rubanets
Affiliation:
Outpatient Department, Precarpathian Regional Clinical Center of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Alprazolam is an anxiolytic, a benzodiazepine derivative of the middle duration of action. It is one of the most frequently prescribed medication for the treatment of anxiety and panic disorder. Under the action of a drug, a person feels incredible ease, a sense of euphoria, absence of problems, a sense of safety.

Objectives

A 55-year woman was admitted to psychiatric clinic in Ivano - Frankivsk.

Methods

She was assesed by the clinicopsychopatological method (clinical interview) and additional methods (MRI, EEG, pathopsycological assessment).

Results

The main findings were: atactic procession, tremor of the limbs and the whole body, poor attention, speech impairment, retarded thinking, fixation and reproductive amnesia with the components of progressive amnesia, change handwriting. The mood is lowered with unstable affect, lack of insight. She reported burning and tingling of the head as a main problem. She developed amotivation, bad activity and drowsiness, bradycardia, decreased blood pressure. She took Alprazolam during a period of 1,5 year in gradually increasing doses. The last dose was 12 tablets of Alprazolam per day. The patient was consulted again in a year. She does not take Alprazolam. She takes valproate and escitalopram. She did not demonstrate severe neurological symptoms which were seen a year ago.

Conclusions

Thus, though alprazolam is one of the best anxiolytic substance it should be prescribed only by the doctor for a short course (no more than 4-5 weeks). The treatment must include psychoeducation in order to make patients be aware about possible addiction and unsafety of prolonged and uncontrolled usage of alprazolam.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.